Navigation Links
Decline in Paternity Rates Following Treatment for Testicular Cancer

A recent study published in the November issue of the Journal of the National Cancer Institute, shows that paternity rates of testicular cancer patients declined after treatment, and patients treated with the higher chemotherapy dose had the lowest chance of becoming fathers. //

Germ-cell testicular cancer is the most common cancer among 20-40 year old men. Many testicular cancer patients are diagnosed at an age at which they are starting a family, and the ability to father children in the future is an important issue for approximately 60% of newly diagnosed patients.

Subfertility or infertility can be associated with the disease itself or with its treatment. Approximately half of all testicular cancer patients have defective spermatogenesis at diagnosis, even before orchiectomy.

Researchers from Norway assessed post-treatment paternity among long-term survivors of testicular cancer whose treatment had followed a modern management approach. A total of 1814 men who had been treated for unilateral testicular cancer in Norway during 1980 through 1994 were invited to participate in a national multi-center follow-up survey in 1998 through 2002.

The participants were allocated to five groups according to the treatment received after orchiectomy, including treatment at relapse (surveillance, retroperitoneal lymph node dissection, radiotherapy, low-dose chemotherapy, and high-dose chemotherapy).

Results obtained depicted that a total of 1433 men were assessable, of whom 827 were fathers at diagnosis. 554 men had attempted post-treatment conception, among whom the overall 15-year actuarial post-treatment paternity rate was 71% without the use of cryopreserved semen. This rate ranged from 48% in the high-dose chemotherapy group to 92% in the surveillance group.

Assisted reproductive technologies were used by 22% of the couples who attempted conception after treatment. Dry ejaculation, treatment group, pretreatment fa therhood, and marital status were statistically significant independent predictors for post-treatment fatherhood, with dry ejaculation as the most important negative factor.

The authors conclude that post-treatment paternity rates in all treatment groups were lower than those in the surveillance group. Patients treated with the higher chemotherapy dose (i.e., more than 850 mg of cisplatin) had the lowest chance of becoming fathers. However, even among these most intensively treated men, almost half were able to father children.

Although the overall paternity rate after treatment for testicular cancer was high, the ability to conceive and the time to conception reflected the intensity of treatment. The authors hope that these data may help inform patients about their future ability to father biological children
'"/>




Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Anemia may Lead to Physical Decline
3. Exercise Can Decrease Mental Decline
4. Folic Acid Retards Mental Decline In Middle Aged Subjects
5. Breastfeeding Decline In Middle East Worries UN
6. Preventing Age-Related Mental Decline By Consuming Vitamin B
7. Drug Use On The Decline Among US Youth
8. Delhi Sees Sharp Decline In Chicken Prices
9. Global Seagrass Decline Affects Shallow-water Ecosystems
10. Decline of Suicide Rates to a Record Low, Holds Promise
11. Contraceptive Use on the Decline among the Poor
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
(Date:10/11/2017)... PARK, Calif. , Oct. 11, 2017  BioPharmX ... national scientific team that developed an innovative way to ... quantity of the delivery of new drugs. ... 2017 Fall Clinical Dermatology Conference will show how researchers ... General Hospital, Harvard Medical School used a suite of ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
Breaking Medicine Technology: